Search

Royal Free patient given months to live ‘cured’ by skin cancer miracle drug

11:11 03 June 2014

Warwick Steele, 64, saw his skin cancer almost disappear after being treated with a new drug at the Royal Free Hospital in Hampstead

Warwick Steele, 64, saw his skin cancer almost disappear after being treated with a new drug at the Royal Free Hospital in Hampstead

Archant

A pioneering new drug trialled at the Royal Free hospital appears to have cured a man with advanced skin cancer who had been given just months to live.

Dr David Chao, consultant from the Royal Free, says the treatment represents a 'paradigm shift' in the fight against cancerDr David Chao, consultant from the Royal Free, says the treatment represents a 'paradigm shift' in the fight against cancer

Doctors say they cannot be certain it was the treatment that led to the “miraculous” outcome for 64-year-old Warwick Steele, but know of no other explanation.

It comes after the trial of drug pembrolizumab, which is the latest in a new generation of treatments that prevent cancers shielding themselves from the immune system.

It was tested on melanoma - the most dangerous form of skin cancer - because the prospects for patients with advanced forms of this disease are so bleak.

Mr Steele, a television engineer from Ruislip, had undergone six months of treatment with pembrolizumab, which is injected into the bloodstream.

Doctors were astonished when after just three months his tumours had almost disappeared. Since then they have shown no sign of returning - and in fact have shrunk even further.

His consultant, Dr David Chao, from the Royal Free in Pond Street, Hampstead, said: “We cannot say for certain that he’s been cured, but he is doing very well. He was aware that without an effective treatment his survival prospects were not good - maybe months.

“Pembrolizumab looks like it has potential to be a paradigm shift for cancer therapy and is firmly helping to establish immunotherapy as one of the most exciting and promising treatments in recent years.

“This is one of several new drugs of this type being produced. What these early trials are showing is that they are fulfilling their promise ridiculously fast.

“Some of these results are really astonishing; almost jaw-dropping. And these drugs may be applicable to many different cancer types, including ones that are hard to treat, such as lung cancer.

“Cancers adapt to treatments, and when they come back they are harder to treat. Can we dream about actually curing some of our patients with very advanced cancer? Once we get the immune system attacking the cancer, can it act independently to keep the cancer under control? We don’t have all the answers yet, but that’s what we’re looking at.”

Just under 70 per cent of the 411 patients taking part in the trial were still alive one year after starting on the treatment.

The result is considered remarkable because all had highly advanced melanoma and a very poor prognosis.

Currently one-year survival rates for untreated patients diagnosed with advanced stage four melanoma are just 10 per cent for men and 35 per cent for women.

Pembrolizumab is a synthetic antibody that blocks a biological pathway called programmed cell death 1 (PD-1) which cancers activate to suppress the immune system.

In healthy individuals, PD-1 is part of the process that applies a “brake” to the immune system and prevents it running out of control.

Without the brake, there is a risk of a harmful inflammatory reaction - a potential serious side-effect of the new drugs.

Pembrolizumab was generally “well tolerated” by the trial patients, according to Dr Chao, but he said responses varied widely between individuals.

Results from the trial were presented at the annual meeting of the American Society of Clinical Oncology in Chicago.

Clinicians do not yet know the true extent of how pembrolizumab might affect survival.

After 18 months, 62 per cent of patients were still alive and undergoing treatment.

In addition, around 80 per cent of patients responded to the drug - an unusually high proportion.

A total of 72 per cent experienced tumour shrinkage, including 39 per cent whose tumours were more than halved in size, according to one kind of assessment.

Additional data showed that the drug also reduced the size of advanced non-small cell lung cancers by up to 47 per cent.

Pembrolizumab’s manufacturer, the pharmaceutical company Merck Sharp & Dohme, is expected to apply for a European licence to market the drug within months.

Each year, around 13,300 people in the UK are diagnosed with melanoma - more than a third of them aged under 55.

Gillian Nuttall, founder of the charity Melanoma UK, said: “Advanced melanoma is a terrible disease with a poor prognosis.

“Pembrolizumab represents the latest advance in a whole raft of new treatments in advanced melanoma which have come through over the past few years.

“The pembrolizumab results are really exciting and could represent a turning point for patients affected by advanced melanoma, giving them a greater chance of survival.”

0 comments

Welcome , please leave your message below.

Optional - JPG files only
Optional - MP3 files only
Optional - 3GP, AVI, MOV, MPG or WMV files
Comments

Please log in to leave a comment and share your views with other Hampstead Highgate Express visitors.

We enable people to post comments with the aim of encouraging open debate.

Only people who register and sign up to our terms and conditions can post comments. These terms and conditions explain our house rules and legal guidelines.

Comments are not edited by Hampstead Highgate Express staff prior to publication but may be automatically filtered.

If you have a complaint about a comment please contact us by clicking on the Report This Comment button next to the comment.

Not a member yet?

Register to create your own unique Hampstead Highgate Express account for free.

Signing up is free, quick and easy and offers you the chance to add comments, personalise the site with local information picked just for you, and more.

Sign up now

Latest Hampstead & Highgate News Stories

Yesterday, 17:25

Anger over the proposed cycle-superhighway CS-11 has fuelled calls for Hampstead to become an independent parish council, granting the area planning powers separate from Camden.

Yesterday, 16:31

The breakfast supervisor, who worked for the chain since 1996, has also received a written apology after being ‘bullied and harassed’

Yesterday, 16:01

Change is afoot in Highgate as a consultation on a new Neighbourhood Plan opens

Yesterday, 15:03

Hampstead High Street and Muswell Hill Broadway could lose their Maison Blanc stores under a review that has been launched into the high-end patisserie chain.

Yesterday, 07:00

Crime campaigners fear gang warfare is spilling onto the leafy streets of Hampstead and Belsize Park after two shootings and a knife attack this month.

Tue, 14:39

Staff will trace Lord Lauderdale’s steps on the journey he may have taken to visit his mistress before Lauderdale House opens once more

Tue, 12:12

The mixed pond on Hampstead Heath will be ‘women only’ for two weeks in October after management confirmed the ladies’ pond will close so that work can be carried out.

Tue, 09:57

Police were called at around 23.20pm to reports of a gunshot last week but there have been no arrests made so far

PROMOTED CONTENT

Interested in purchasing a flat and want to know the rules, rights and regulations as a leaseholder? Or maybe you are already a leaseholder and want to find out more about extending your lease?

Scores of people visited the opening of Composite Door Master’s first public showroom in Hayes at the weekend, where they were treated to a spectacular show by award winning magician, Marc Oberon.

You’ve got cash, you’ve got style and you’ve got a bursting social calendar, but no time. These Crouch End studio suites to rent could be your dream come true.

Newsletter Sign Up

Sign up to the following newsletters:

Most read Hampstead & Highgate news

HOT JOBS

Show Job Lists

Property Newsletter Sign-up

Get the latest North London property news and features straight to your inbox with our regular newsletter

I am also happy to receive other emails...
Fields marked with a * are mandatory
Email Marketing by e-shot

Competitions

If you’re obsessed with Apple or just love a good gadget, this is a prize that will blow you away! An incredible £3,333 to spend on Apple goodies! How would you like to be the proud new owner of the Apple Watch?

As we grow older it becomes more and more important to have means to travel about safely and quickly. Our friendship groups and families grow and the need to have a car that is not only safe but also fast and big enough for all our needs is ever more important. There are many cars on the market for such needs but none deals with them as efficiently or as neatly as a VW Golf Estate. These cars are build strong, long lasting and spacious for a reason. They cater to the needs of many and are some of the most popular cars currently on the market.

Digital Edition

cover

Enjoy the
Hampstead & Highgate Express
e-edition today

Subscribe

Education and Training

cover

Read the
Education and Training
e-edition today

Read Now